top of page
The Sound of Evolution
Daclizumab
Mechanism of action:
Daclizumab is a monoclonal antibody. Daclizumab specifically binds to the interleukin-2 receptor α chain (IL-2Rα, also known as CD25), blocking IL-2 from binding to the receptor and thereby inhibiting T cell proliferation and activation.
Reference(s):
1. Shamsi TS et al. (2005). Allogeneic peripheral blood stem cell transplant (PBSCT) using anti-IL2 receptor antibody daclizumab for the prevention of acute graft versus host disease in steroid refractory Diamond Blackfan anaemia: a case report. J Pak Med Assoc.
2. Przepiorka D et al. (2000). Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood.
bottom of page